High-density lipoprotein mimetics: promises and challenges

Sviridov, Dmitri; Remaley, Alan T.

doi:10.1042/bj20150832

Cited by 28 publications

(18 citation statements)

References 106 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HDL plays a central role in FFA clearance and reverse cholesterol transport. Besides, HDL and its mimetics also show anti-oxidant, anti-thrombotic and anti-apoptotic functions 15 . Several researchers figured out that a low amount of HDL-C, which has anti-inflammatory properties, can in turn lead to a more severe systemic inflammatory response 25 .…”

Section: Discussionmentioning

confidence: 99%

“…In addition to playing a central role in reverse cholesterol transport (RCT) in vascular protection, HDL and its mimetics have several other functions including antioxidant, antithrombotic and anti-apoptotic functions. The anti-inflammatory function of HDL is investigated intensively, affecting both local (such as expression of adhesion molecules on endothelium) and systemic immune systems (such as expression of adhesion molecules and cytokine secretion by monocytes) 15 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Decreased high density lipoprotein cholesterol is an independent predictor for persistent organ failure, pancreatic necrosis and mortality in acute pancreatitis

Zhang

Guo

et al. 2017

Sci Rep

View full text Add to dashboard Cite

High density lipoprotein cholesterol (HDL-C) has been reported as a significant indicator of systemic inflammation. The association underlying HDL-C and persistent organ failure (POF), pancreatic necrosis (PNec) and mortality in acute pancreatitis (AP) has not been evaluated. From 2007 to 2016, consecutive AP patients with admission lipid profiles assessment were included in this study. The association of HDL-C value and other lipids with outcomes was explored with Cox proportional regression models, which were adjusted for confounding factors. 1131 consecutive AP patients were clinically eligible. Overall, 17.9% of the patients developed with POF, 27.1% experienced PNec, and 6.7% died during hospitalization. Lower HDL-C median (<1.06 mmol/L) was identified as an independent prognostic factor of the outcomes. Moreover, there was a positive trend for the association across increasing HDL-C quartiles and POF, PNec and mortality after multivariable analysis (p values were <0.001, <0.001 and 0.043, respectively). The AUC of HDL-C for the outcomes were comparable to that of Ranson score for diagnosing POF (0.778 vs. 0.678; P < 0.001), PNec (0.734 vs. 0.701; P = 0.143) and mortality (0.768 vs. 0.745; P = 0.516). Decreased HDL-C value is an independent risk factor for the incidence of POF, PNec and in-hospital mortality in AP.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Decreased high density lipoprotein cholesterol is an independent predictor for persistent organ failure, pancreatic necrosis and mortality in acute pancreatitis

Zhang

Guo

et al. 2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Given some of the variable effects of the above drugs, there has also been mounting interest in the development of HDL analogues and apoA-I mimetic peptides for the treatment of vascular diseases [ 140 , 152 ]. Studies of such novel compounds have, so far, mainly been confined to in vitro studies or animal models, however, several do show promise.…”

Section: Hdl-modifying Treatment Approaches In Diabetesmentioning

confidence: 99%

The Role of High-Density Lipoproteins in Diabetes and Its Vascular Complications

Wong

Nicholls

Tan

et al. 2018

IJMS

View full text Add to dashboard Cite

Almost 600 million people are predicted to have diabetes mellitus (DM) by 2035. Diabetic patients suffer from increased rates of microvascular and macrovascular complications, associated with dyslipidaemia, impaired angiogenic responses to ischaemia, accelerated atherosclerosis, and inflammation. Despite recent treatment advances, many diabetic patients remain refractory to current approaches, highlighting the need for alternative agents. There is emerging evidence that high-density lipoproteins (HDL) are able to rescue diabetes-related vascular complications through diverse mechanisms. Such protective functions of HDL, however, can be rendered dysfunctional within the pathological milieu of DM, triggering the development of vascular complications. HDL-modifying therapies remain controversial as many have had limited benefits on cardiovascular risk, although more recent trials are showing promise. This review will discuss the latest data from epidemiological, clinical, and pre-clinical studies demonstrating various roles for HDL in diabetes and its vascular complications that have the potential to facilitate its successful translation.

show abstract

“…Given these shortcomings, the advantages of fully synthetic products over naturally derived components are lower costs for production and higher flexibility in modifying the structure of rHDL. However, to enable translation scalability of manufacturing measures like yields and sample purity have also to be considered [101,170]. In this respect, the implementation of apo-AI peptide mimetics holds significant promise.…”

Section: Challenges Advantages and Limitationsmentioning

confidence: 99%

Artificial High Density Lipoprotein Nanoparticles in Cardiovascular Research

2019

View full text Add to dashboard Cite

Lipoproteins are endogenous nanoparticles which are the major transporter of fats and cholesterol in the human body. They play a key role in the regulatory mechanisms of cardiovascular events. Lipoproteins can be modified and manipulated to act as drug delivery systems or nanocarriers for contrast agents. In particular, high density lipoproteins (HDL), which are the smallest class of lipoproteins, can be synthetically engineered either as nascent HDL nanodiscs or spherical HDL nanoparticles. Reconstituted HDL (rHDL) particles are formed by self-assembly of various lipids and apolipoprotein AI (apo-AI). A variety of substances including drugs, nucleic acids, signal emitting molecules, or dyes can be loaded, making them efficient nanocarriers for therapeutic applications or medical diagnostics. This review provides an overview about synthesis techniques, physicochemical properties of rHDL nanoparticles, and structural determinants for rHDL function. We discuss recent developments utilizing either apo-AI or apo-AI mimetic peptides for the design of pharmaceutical rHDL formulations. Advantages, limitations, challenges, and prospects for clinical translation are evaluated with a special focus on promising strategies for the treatment and diagnosis of atherosclerosis and cardiovascular diseases.

show abstract

High-density lipoprotein mimetics: promises and challenges

Cited by 28 publications

References 106 publications

Decreased high density lipoprotein cholesterol is an independent predictor for persistent organ failure, pancreatic necrosis and mortality in acute pancreatitis

Decreased high density lipoprotein cholesterol is an independent predictor for persistent organ failure, pancreatic necrosis and mortality in acute pancreatitis

The Role of High-Density Lipoproteins in Diabetes and Its Vascular Complications

Artificial High Density Lipoprotein Nanoparticles in Cardiovascular Research

Contact Info

Product

Resources

About